HomeNewsBusinessPersonal FinanceInsurers face massive rise in non-COVID-19 claims in July, but health coverage still low

Insurers face massive rise in non-COVID-19 claims in July, but health coverage still low

The claims are mainly for treatments of cancer, dialysis, cataract surgeries and cardiac ailments

September 03, 2020 / 10:17 IST
Story continues below Advertisement

Amit Chhabra 

COVID-19 positive cases in India have surged past the 3.65 million figure. In the last few months, only a little more than 1 lakh people have so far utilised their health insurance policies for the treatment of the novel coronavirus. According to numbers collated by insurance companies, approximately only 1,00,000 claims have come to insurers for a settlement involving a cumulative amount of Rs 1,644 crore—this works out to an incurred expenditure of Rs 1.64 lakh, on an average, per policyholder. The 1 Lakh claims when viewed against the over 3.65 million COVID-19 cases translate to just 2.7 per cent of the individuals who tested positive and had some kind of health insurance coverage.

Story continues below Advertisement

On the other hand, general and specialised health insurers are witnessing a steady rise in non-COVID-related medical insurance claims as normalcy returns after the stringent lockdown was eased by the government. There has been a 64 per cent increase in July for such claims versus average claims in April, May and June. Of these claims, only 10 per cent are COVID-19 related. The rise in claims is mostly coming from elective procedures that were postponed on account of COVID-19 in the last few months. During the lockdown period, non-life insurers saw an almost 40 per cent drop in non-COVID claims. The claims are mainly for treatments of cancer, dialysis, cataract surgeries and cardiac ailments.

Time to prioritise health insurance

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show